Last updated: October 26, 2026
IDELVION, CSL Behring’s recombinant factor IX albumin-fusion protein for hemophilia B, is a mature specialty biologic with durable commercial value but rising competitive pressure. Its principal advantages are extended half-life, reduced infusion frequency, and established physician adoption. Its main risks are gene therapies, competing extended-half-life factor IX products, biosimilar entry after the U.S. biologic exclusivity period, and treatment switching among severe hemophilia B patients.
CSL does not publicly disclose IDELVION revenue as a standalone line item. Financial analysis therefore relies on CSL Behring segment performance, company disclosures, prescription and product-positioning data, regulatory exclusivity, and competitive developments.
What is IDELVION and how does it generate revenue?
IDELVION is eftrenonacog alfa, a recombinant coagulation factor IX linked to recombinant albumin. The albumin-fusion structure extends circulation time compared with conventional factor IX replacement products. The FDA approved IDELVION on March 4, 2016, for adults and children with hemophilia B for routine prophylaxis, control of bleeding episodes, and perioperative management.[1]
The product generates revenue through recurring replacement therapy. Patients with severe hemophilia B often require lifelong prophylaxis, creating a comparatively predictable treatment base. Revenue depends on:
- Number of diagnosed and treated hemophilia B patients
- Share of patients receiving prophylaxis rather than on-demand therapy
- Product share within extended-half-life factor IX
- Dosing frequency and patient weight
- Reimbursement and specialty-pharmacy access
- Switching to gene therapy or competing factor products
- Use in pediatric patients, surgery, and breakthrough bleeding
IDELVION is administered intravenously. The FDA label supports individualized prophylaxis, with dosing intervals that can extend beyond conventional factor IX regimens in appropriate patients.[1]
What is the financial trajectory for IDELVION?
IDELVION’s financial trajectory is best described as launch growth followed by mature-franchise expansion and increasing competitive normalization.
| Period |
Commercial position |
Financial interpretation |
| 2016 |
U.S. launch after FDA approval |
Initial revenue build from conversion of conventional factor IX users |
| 2017-2019 |
Expansion of prophylaxis use and international availability |
Growth supported by extended-half-life positioning and CSL’s specialty-care infrastructure |
| 2020-2022 |
Mature product with recurring demand |
Pandemic disruption was less severe than in elective-care markets because hemophilia treatment remained medically necessary |
| 2022-2024 |
Increased competition from gene therapy and new factor IX options |
Continued franchise value, but lower long-term growth potential |
| 2025 onward |
Mature biologic facing patent, exclusivity, and treatment-modality risks |
Revenue durability depends on switching resistance, access, and lifecycle management |
CSL reports financial results primarily at the CSL Behring and business-group levels rather than by individual brands. Public filings do not provide a verified annual IDELVION revenue series.[2] This prevents a defensible product-level compound annual growth rate or market-share calculation.
CSL Behring remains the economic engine of CSL Limited, with sales driven by immunoglobulins, specialty products, and plasma-derived therapies. IDELVION is strategically important because it adds a recombinant, specialty hematology product to a portfolio that otherwise has substantial exposure to plasma collection, immunoglobulin demand, and manufacturing capacity.[2]
The product’s commercial profile has several attractive characteristics:
- Hemophilia B is a chronic disease with concentrated specialist prescribing.
- Treatment is reimbursed through specialty channels rather than ordinary retail pharmacy.
- Patients who achieve stable bleeding control often have limited incentive to switch.
- CSL owns the global commercial infrastructure and manufacturing capabilities.
- The product can be used across pediatric and adult populations.
The limitations are equally material. The treated population is small, factor replacement is expensive, and product demand is exposed to a limited number of high-value patients. The arrival of one-time or potentially one-time gene therapies changes the revenue model from recurring annual sales to upfront treatment revenue.
How does IDELVION compare with competing hemophilia B drugs?
IDELVION competes primarily with other factor IX replacement products rather than with general hematology drugs.
| Product |
Active ingredient |
Company |
Product type |
Main competitive position |
| IDELVION |
Eftrenonacog alfa |
CSL Behring |
Albumin-fusion recombinant factor IX |
Extended half-life and established prophylaxis use |
| ALPROLIX |
Eftrenonacog alfa |
Sanofi/Sobi |
Fc-fusion recombinant factor IX |
Direct extended-half-life competitor |
| Rebinyn |
Nonacog beta pegol |
Novo Nordisk |
PEGylated recombinant factor IX |
Extended half-life, especially relevant in prophylaxis and surgery |
| BeneFIX |
Nonacog alfa |
Pfizer |
Conventional recombinant factor IX |
Established product with shorter dosing interval |
| IXINITY |
Trenonacog alfa |
Medexus Pharmaceuticals |
Conventional recombinant factor IX |
Smaller commercial competitor |
| Hemgenix |
Etranacogene dezaparvovec |
CSL/uniQure |
AAV gene therapy |
Potential one-time treatment for eligible adults |
| BEQVEZ |
Fidanacogene elaparvovec |
Pfizer |
AAV gene therapy |
One-time gene therapy option for eligible adults |
ALPROLIX is the closest established branded competitor because both products are extended-half-life recombinant factor IX therapies. Rebinyn competes through PEGylation and dosing flexibility. Conventional products remain relevant where clinicians prioritize familiarity, formulary access, or lower acquisition cost.
The most disruptive competitors are Hemgenix and BEQVEZ. Hemgenix was approved by the FDA in November 2022 for certain adults with hemophilia B who use factor IX prophylaxis, have a history of serious bleeding, and lack neutralizing antibodies to the AAV5 vector.[3] BEQVEZ was approved in April 2024 for adults with moderate to severe hemophilia B who meet specified clinical criteria.[4]
Gene therapy does not immediately eliminate factor IX demand. Eligibility restrictions, durability questions, liver-related monitoring, manufacturing capacity, payer approval, and patient preference constrain adoption. It does, however, create a credible long-term ceiling on IDELVION’s growth among eligible adult patients.
When does IDELVION lose U.S. biologic exclusivity?
IDELVION’s U.S. reference-product biologic exclusivity began with FDA approval on March 4, 2016. The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity for a licensed biologic, subject to statutory rules governing the first licensure date and pediatric exclusivity.[5]
On that basis, the principal U.S. reference-product exclusivity date is March 4, 2028. This date does not guarantee immediate biosimilar launch. A biosimilar applicant must complete the 351(k) pathway, resolve patent and regulatory barriers, and obtain approval before commercial entry.
| U.S. milestone |
Date or status |
| FDA approval |
March 4, 2016 |
| Reference biologic exclusivity |
Generally through March 4, 2028 |
| Regulatory pathway for follow-on products |
Section 351(k) biosimilar pathway |
| Orange Book listing |
Not the principal biologic reference; Purple Book is the relevant FDA resource |
| Likely commercial risk |
Biosimilar competition after approval and patent resolution |
The 2028 date is a regulatory exclusivity milestone, not necessarily the first possible entry date for every competitor. Patent protection, litigation, settlement terms, manufacturing readiness, and interchangeability decisions can move actual launch timing.
What patents protect IDELVION?
IDELVION is protected through a combination of biologic exclusivity, patents covering the albumin-fusion molecule and production technology, manufacturing know-how, regulatory data, trademarks, and commercial trade secrets.
Unlike small-molecule drugs, IDELVION does not rely on a conventional Orange Book patent strategy. Biologic patent information is addressed through the Purple Book and the BPCIA patent-exchange process. Publicly available product information and regulatory materials do not provide a complete, consolidated patent-life table equivalent to a typical small-molecule Orange Book entry.
The main IP categories are:
Molecule and fusion-protein patents
These may cover the factor IX-albumin fusion structure, amino-acid sequence, linker arrangements, and functional variants. Such claims can be important against biosimilars that use a similar albumin-fusion architecture.
Manufacturing and cell-culture patents
Recombinant protein expression, purification, formulation, and process controls can create practical barriers even when broad composition claims are vulnerable. Manufacturing consistency is especially important for coagulation factors because regulators require close characterization of potency, impurities, aggregation, and activity.
Formulation and stability protection
Formulation claims may address storage, concentration, excipients, reconstitution, and stability. These patents are usually less powerful than composition claims against a biosimilar but can complicate substitution or support settlement leverage.
Method-of-use protection
Method claims may cover prophylactic dosing, treatment of bleeding episodes, perioperative use, or administration schedules. Method-of-use patents generally have narrower enforcement value than composition claims because a biosimilar manufacturer may attempt a carve-out from patented indications.
What is the Orange Book status of IDELVION?
IDELVION is a biologic licensed under a biologics license application, not a conventional small-molecule new drug application. The Orange Book is therefore not the primary source for its regulatory exclusivity or patent information. The relevant framework is:
- FDA biologic licensing under the Public Health Service Act
- Twelve-year reference-product exclusivity
- Purple Book identification of licensed biologics
- BPCIA biosimilar approval procedures
- Patent litigation under the BPCIA framework and applicable federal patent law
A Paragraph IV certification is a Hatch-Waxman mechanism associated with small-molecule abbreviated new drug applications. It is not the standard pathway for challenging IDELVION. A biosimilar applicant would instead use the BPCIA patent-information exchange and litigation process.
Which companies are challenging IDELVION’s market position?
The principal competitive threats come from established factor manufacturers and gene-therapy developers rather than a disclosed wave of conventional generic challengers.
| Company |
Product or strategy |
Risk to IDELVION |
| Sanofi/Sobi |
ALPROLIX |
Direct extended-half-life factor IX competition |
| Novo Nordisk |
Rebinyn |
Competes on half-life and dosing flexibility |
| Pfizer |
BEQVEZ and legacy factor products |
Gene therapy and replacement-factor competition |
| CSL/uniQure |
Hemgenix |
Internal portfolio cannibalization risk but controlled by CSL |
| Potential biosimilar manufacturers |
Follow-on factor IX biologics |
Price erosion after regulatory and patent barriers fall |
No widely reported IDELVION-specific Paragraph IV litigation is the central market event. The main legal risk is future BPCIA litigation involving biosimilar applicants, patent validity, infringement, and launch timing.
How strong is the IDELVION patent estate?
The estate is commercially meaningful but not immune to erosion. Its strongest protections are likely the combination of biologic exclusivity, molecule-specific technology, manufacturing complexity, and CSL’s control of specialized production. Its weaker areas are narrow method-of-use patents, formulation claims that can be designed around, and the eventual expiration of core composition claims.
Patent strength should be evaluated against four factors:
- Whether broad claims cover the commercially relevant factor IX-albumin structure.
- Whether claims survive validity challenges based on prior art and obviousness.
- Whether a biosimilar can use a different process or formulation.
- Whether regulatory exclusivity expires before key patent disputes are resolved.
The practical barrier to entry may therefore exceed the legal patent term. A biosimilar manufacturer must reproduce a complex biologic, establish comparability, secure manufacturing capacity, and obtain payer access.
What generic or biosimilar entry risks exist?
Biosimilar entry is a medium-term risk rather than an immediate revenue event. The most likely effects are:
- Lower net prices in tender-driven markets
- Rebates to preserve preferred formulary status
- Reduced new-patient starts
- Greater switching among stable adult patients
- Pressure on hospital and specialty-pharmacy contracts
- Regional divergence based on substitution rules
The risk is lower in pediatric patients and patients with a strong treatment history, where clinicians may resist switching absent meaningful savings. The risk is higher in public tenders, adult populations, and markets with automatic or pharmacist-led substitution.
Biosimilar entry may first affect price rather than volume. IDELVION could retain substantial unit demand while experiencing lower net realized revenue.
What licensing deals support IDELVION?
IDELVION relies on CSL Behring’s ownership and commercialization platform, combined with albumin-fusion technology that CSL obtained through earlier strategic technology transactions. The product’s development reflects CSL’s use of recombinant protein and albumin-fusion capabilities rather than a conventional external licensing model comparable to a co-commercialized small molecule.[6]
The most important related transaction is CSL’s relationship with uniQure for Hemgenix. CSL commercializes Hemgenix under a global licensing and collaboration arrangement with uniQure.[7] That relationship creates both a competitive hedge and a portfolio conflict: CSL can retain economics from hemophilia B patients who move from factor replacement to gene therapy, while IDELVION bears potential recurring-revenue erosion.
What is the outlook for IDELVION revenue?
The base case is stable-to-moderate decline in mature markets, partly offset by international growth, pediatric use, and continued prophylaxis demand.
| Scenario |
Revenue effect |
Main drivers |
| Upside |
Stable or modest growth |
Continued factor preference, slower gene-therapy adoption, strong emerging-market access |
| Base case |
Gradual erosion |
Mature patient base, competitive factor products, selective gene-therapy switching |
| Downside |
Accelerated decline |
Broad Hemgenix and BEQVEZ uptake, biosimilar entry, payer pressure, loss of key accounts |
Revenue exposure is concentrated in a relatively small number of high-value patients. A small number of successful gene-therapy treatments can therefore have a disproportionate impact on annual product revenue. The impact will vary by geography because reimbursement, gene-therapy infrastructure, and treatment eligibility differ across the United States, Europe, and other markets.
CSL’s ownership of both IDELVION and Hemgenix reduces enterprise-level exposure compared with a company selling only factor replacement. It does not eliminate product-level cannibalization. The portfolio may shift from recurring factor revenue toward upfront gene-therapy revenue with different recognition patterns, manufacturing economics, and payer risk.
How does IDELVION compare with Hemgenix and BEQVEZ?
| Factor |
IDELVION |
Hemgenix |
BEQVEZ |
| Treatment model |
Repeated replacement therapy |
One-time gene therapy |
One-time gene therapy |
| Administration |
Intravenous infusions |
One-time intravenous infusion |
One-time intravenous infusion |
| Patient population |
Broad hemophilia B population, subject to label |
Selected adults |
Selected adults |
| Revenue model |
Recurring annual sales |
Upfront treatment revenue |
Upfront treatment revenue |
| Key risk |
Biosimilars and competing factors |
Durability, eligibility, payer approval |
Durability, eligibility, safety and payer approval |
| Commercial maturity |
Established |
Commercially available |
Newly commercial relative to IDELVION |
IDELVION retains advantages in reversibility, clinical familiarity, and use across patients who are not eligible for gene therapy. Gene therapy has the stronger long-term disruption potential because it can reduce or eliminate routine factor use in successfully treated patients.
What is the investment view of IDELVION?
IDELVION is a cash-generating mature specialty biologic rather than a primary growth asset. Its value lies in recurring demand, specialist prescribing, CSL’s global infrastructure, and manufacturing barriers. Its valuation contribution should be discounted for:
- U.S. biologic exclusivity ending in 2028
- Potential biosimilar competition
- Gene-therapy substitution
- Price competition from ALPROLIX and Rebinyn
- Small patient population and concentration risk
- Limited public disclosure of product-level revenue
The strongest commercial defense is not a single patent. It is the combined effect of physician familiarity, patient stability, supply reliability, specialty distribution, manufacturing complexity, and CSL’s ability to offer both factor replacement and gene therapy.
Key Takeaways
- IDELVION is a mature, high-value hemophilia B biologic with recurring prophylaxis revenue.
- CSL does not disclose standalone IDELVION sales, so exact revenue and product-level CAGR calculations are not publicly verifiable.
- U.S. reference-product biologic exclusivity generally runs through March 4, 2028.
- Biosimilar challenges would proceed under the BPCIA framework, not through a conventional Paragraph IV filing.
- ALPROLIX and Rebinyn are the main extended-half-life factor IX competitors.
- Hemgenix and BEQVEZ create the largest long-term threat by converting recurring factor revenue into one-time gene-therapy treatment.
- CSL’s ownership of Hemgenix provides a hedge against IDELVION switching but also creates internal portfolio cannibalization.
- The likely base case is durable cash generation followed by gradual revenue erosion as gene therapy, biosimilars, and payer pressure expand.
FAQs
Is IDELVION a biologic or a generic drug?
IDELVION is a recombinant biologic licensed under a biologics license application. It is not a conventional generic drug.
Can a biosimilar be automatically substituted for IDELVION?
Automatic substitution depends on FDA interchangeability status and state pharmacy laws. Biosimilar approval alone does not necessarily create automatic substitution rights.
Is IDELVION covered by the Orange Book?
The Orange Book is not the primary reference for IDELVION. The Purple Book and BPCIA framework are more relevant to its biologic status, exclusivity, and biosimilar competition.
Does Hemgenix eliminate the need for IDELVION?
No. Hemgenix is limited to eligible patients, and many patients may remain on factor IX prophylaxis because of eligibility, safety, durability, payer, or preference considerations.
Who owns IDELVION?
CSL Behring, a division of CSL Limited, owns and commercializes IDELVION.
References
- U.S. Food and Drug Administration. (2016). IDELVION (eftrenonacog alfa) prescribing information.
- CSL Limited. (2024). Annual report 2024.
- U.S. Food and Drug Administration. (2022). FDA approves first gene therapy for adults with hemophilia B.
- U.S. Food and Drug Administration. (2024). FDA approves gene therapy for adults with hemophilia B.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Patient Protection and Affordable Care Act, Pub. L. No. 111-148.
- CSL Behring. (2016). FDA approves IDELVION, the first and only recombinant albumin-fusion protein for hemophilia B.
- CSL Limited. (2024). Annual report 2024: Hemgenix collaboration and CSL Behring commercial portfolio.
